SCHEMBL9769185

SCHEMBL9769185

CCCCCCN1CCN(CCCCCC)C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.47
PTGS1 P23219 3/20 0.47
PTGS2 P35354 3/20 0.47
MGLL Q99685 3/20 0.47
FAAH O00519 2/20 0.47
ALOX5 P09917 2/20 0.46
S1PR1 P21453 1/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
ALDH1A1 P00352 3/20 0.41
CYP1A1 P04798 2/20 0.41
GNAI3 P08754 1/20 0.41
GNAO1 P09471 1/20 0.41
GNAI1 P63096 1/20 0.41
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
TP53 P04637 1/20 0.40
HSP90AA1 P07900 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31093244 1.00 GBA1 (0.47) GBA1PTGS1PTGS2MGLLFAAH
SCHEMBL31093212 1.00 GBA1 (0.47) GBA1PTGS1PTGS2MGLLFAAH
SCHEMBL9769271 1.00 GBA1 (0.47) GBA1PTGS1PTGS2MGLLFAAH
SCHEMBL9617015 1.00 GBA1 (0.47) GBA1PTGS1PTGS2MGLLFAAH
SCHEMBL4421172 0.98 GBA1 (0.44) GBA1PTGS1PTGS2MGLLFAAH
SCHEMBL8392265 0.96 GBA1 (0.45) GBA1PTGS1PTGS2MGLLFAAH
SCHEMBL17836960 0.91 ALOX5 (0.47) GBA1PTGS1PTGS2MGLLFAAH
SCHEMBL4424409 0.91 MEN1 (0.45) GBA1MGLLALOX5S1PR1BCHE
SCHEMBL10848072 0.90 GBA1 (0.41) GBA1PTGS1PTGS2MGLLFAAH
SCHEMBL19817111 0.90 GBA1 (0.42) GBA1PTGS1PTGS2MGLLFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-5066774-A Method for the production of light colored aromatic sulfide/sulfone polymers with 1,3-dialkyl-2-imidazolidinone diluent PHILLIPS PETROLEUM COMPANY (US) 1991-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 GBA1 503/4885PTGS1 4765/4885PTGS2 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.